The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 21 February 2006 doi:10.1084/jem.20051520
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 3, 573-582
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2738K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, W. Q.
Right arrow Articles by Durum, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, W. Q.
Right arrow Articles by Durum, S. K.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

IL-7 promotes T cell proliferation through destabilization of p27Kip1

Wen Qing Li1, Qiong Jiang1, Eiman Aleem2, Philipp Kaldis2, Annette R. Khaled1, and Scott K. Durum1

1 Laboratory of Molecular Immunoregulation and 2 Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD 21702

CORRESPONDENCE Scott K. Durum: durums{at}mail.ncifcrf.gov

Interleukin (IL)-7 is required for survival and homeostatic proliferation of T lymphocytes. The survival effect of IL-7 is primarily through regulation of Bcl-2 family members; however, the proliferative mechanism is unclear. It has not been determined whether the IL-7 receptor actually delivers a proliferative signal or whether, by promoting survival, proliferation results from signals other than the IL-7 receptor. We show that in an IL-7–dependent T cell line, cells protected from apoptosis nevertheless underwent cell cycle arrest after IL-7 withdrawal. This arrest was accompanied by up-regulation of the cyclin-dependent kinase inhibitor p27Kip1 through a posttranslational mechanism. Overexpression of p27Kip1 induced G1 arrest in the presence of IL-7, whereas knockdown of p27Kip1 by small interfering RNA promoted S phase entry after IL-7 withdrawal. CD4 or CD8 T cells transferred into IL-7–deficient hosts underwent G1 arrest, whereas 27Kip1-deficient T cells underwent proliferation. We observed that IL-7 withdrawal activated protein kinase C (PKC){theta} and that inhibition of PKC{theta} with a pharmacological inhibitor completely blocked the rise of p27Kip1 and rescued cells from G1 arrest. The conventional pathway to breakdown of p27Kip1 is mediated by S phase kinase-associated protein 2; however, our evidence suggests that PKC{theta} acts via a distinct, unknown pathway inducing G1 arrest after IL-7 withdrawal from T cells. Hence, IL-7 maintains T cell proliferation through a novel pathway of p27Kip1 regulation.


Abbreviations used: CDK, cyclin-dependent kinase; CKI, CDK inhibitor; Cks1, CDK subunit 1; KPC, Kip1 ubiquitination-promoting complex; PI, propidium iodide; PKC, protein kinase C; siRNA, small interfering RNA; Skp2, S phase kinase-associated protein 2.

A.R. Khaled's present address is University of Central Florida, Orlando, FL 32826.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Dividing with IL-7
Heather L. Van Epps
J. Exp. Med. 2006 203: 485a. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS